REMICADE (infliximab) Patient Assistance Program
Don’t let the high cost of brand specialty TNF biologics stand between you and the treatment you need. We help eligible patients access Remicade (infliximab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Remicade (infliximab) is FDA-approved for moderately to severely active Crohn's disease and ulcerative colitis (in adults and pediatric patients 6 and older), moderately to severely active rheumatoid arthritis (with methotrexate), active ankylosing spondylitis, active psoriatic arthritis, and chronic severe plaque psoriasis. It is given as an IV infusion every 8 weeks for maintenance.
- Without assistance, brand Remicade infusions cost commonly run $4,500–$7,000+ each. Multiple FDA-approved biosimilars (Inflectra, Renflexis, Avsola, Ixifi) are available at significantly lower cost.
- Through AffordMyPrescriptions, qualifying patients can access Remicade (or biosimilar) for a flat $69.95 per month — our advocacy team manages the entire enrollment, infusions, and renewal process.
- Multiple FDA-approved infliximab biosimilars provide significant savings — Inflectra, Renflexis, Avsola, and Ixifi are widely available at major infusion centers.
What Is Remicade Prescription Assistance Program?
The Remicade Prescription Assistance Program is a manufacturer-sponsored initiative that provides Remicade infusions at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for patients with IBD or inflammatory arthritis who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, gastroenterology/rheumatology coordination, TB and HBV screening, infusion scheduling, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion-schedule coordination and annual re-certification — so you focus on your health, not paperwork.
Pharmacy Price Comparison
- Without assistance, brand Remicade infusions cost roughly $4,500–$7,000+ each. Multiple biosimilars are available at significantly lower cost. A Patient Assistance Program is the meaningful path for brand pricing — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Per IV infusion (brand) | ~$5,500.00 | Save ~$5,430/dose |
| Per IV infusion (biosimilar) | ~$2,200.00 | Save ~$2,130/dose |
| Every 8 weeks maintenance | ~$2,750/mo | Save thousands/mo |
| Annual cost (brand) | ~$36,000+ | Save ~$35,000+/yr |
| Annual cost (biosimilar) | ~$14,000+ | Save thousands/yr |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Remicade Prescription Program?
The Patient Assistance Program is free to apply for and provides Remicade infusions at little or no medication cost if approved. But the process involves detailed applications, prescriber coordination, TB and HBV screening documentation, infusion scheduling, and ongoing renewal management. Our $69.95/month service covers full advocacy. With multiple Remicade biosimilars available at significantly lower cost, we’ll guide you to the most cost-effective path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Remicade:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $4,500–$7,000+ (brand) / lower for biosimilars per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Remicade assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Remicade Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Remicade:
Remicade (infliximab) is an intravenous (IV) chimeric anti-TNF-alpha monoclonal antibody used to treat several immune-mediated inflammatory conditions — moderate to severe Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. It was the first TNF inhibitor approved (1998) and remains a foundational therapy.
How Remicade Works:
Remicade is a monoclonal antibody that targets TNF-alpha, a key protein involved in overactive immune signaling. By binding to and neutralizing TNF-alpha, the medication interrupts the inflammatory cascade responsible for conditions like RA, IBD, and psoriasis. Its intravenous delivery allows for higher, weight-based dosing, which is particularly beneficial for managing complex intestinal inflammation.
Form and use:
Administered as an IV infusion in a clinical setting, Remicade follows a weight-based dosing schedule. Patients typically receive an induction phase at Weeks 0, 2, and 6, followed by maintenance infusions every 8 weeks. Depending on the patient’s response, providers may increase the dose or shorten the interval between treatments, and premedication may be used to minimize infusion reaction.
Generic availability:
Several FDA-approved biosimilars for Remicade (infliximab), such as Inflectra, Renflexis, and Avsola, are available in the U.S. and generally offer a lower-cost alternative to the brand. The choice between the original brand and a biosimilar often depends on insurance coverage, clinic contracts, and the prescriber’s decision. While chemically similar, these biosimilars provide additional options for managing chronic inflammatory diseases.
Warnings:
Remicade carries boxed warnings for serious infections, including tuberculosis (TB) reactivation and sepsis, as well as risks of certain malignancies like lymphoma. Patients must undergo TB screening before starting therapy and are monitored for heart failure, liver toxicity, and demyelinating diseases. Infusion reactions can occur, and the risk of specific lymphomas is higher in younger patients using the drug alongside other immunomodulators
FAQ (Frequently Asked Questions)
How Much Does Remicade Cost Without Insurance?
Per-infusion costs commonly run $4,500–$7,000+ for brand Remicade. Biosimilars are typically 60% cheaper. Annual costs for maintenance commonly reach $36,000+ for brand. Through AffordMyPrescriptions, qualifying patients receive Remicade (or biosimilar) at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Are Biosimilars To Remicade The Same Medicine?
Biosimilars (Inflectra, Renflexis, Avsola, Ixifi) are FDA-approved as highly similar to and clinically equivalent to brand Remicade (infliximab). They contain the same active ingredient and produce the same clinical results. Whether your infusion is filled as brand or biosimilar depends on your prescriber and infusion site — for many patients, the biosimilar at significantly lower cost is the right path
How Is Remicade Given?
Remicade is given as an IV infusion (typically 2-hour duration) in a clinic, infusion center, or hospital outpatient setting. Dosing is weight-based at 5 mg/kg, given at Weeks 0, 2, and 6 Remicade is given as an IV infusion (typically 2-hour duration) in a clinic, infusion center, or hospital outpatient setting. Dosing is weight-based at 5 mg/kg, given at Weeks 0, 2, and 6 (induction), then every 8 weeks thereafter. Some patients need higher doses or shorter intervals. Premedication may be given to reduce infusion reactions.
Do I Need Tests Before Starting Remicade
Yes. Patients are typically screened for tuberculosis (latent and active) and hepatitis B virus before starting Remicade. Your prescriber will review your medical history, including any history of heart failure, demyelinating disease, recurrent infections, or vaccination needs.
Can I Get Remicade Through The PAP If I Have Medicare?
Yes. Medicare beneficiaries can typically qualify for Remicade Patient Assistance, especially if you face significant out-of-pocket costs under medical or pharmacy benefits. The manufacturer’s commercial copay assistance program is reserved for commercially insured patients only.
What If My Application Is Denied?
If your initial application is denied, we explore alternatives — switching to a Remicade biosimilar at significantly lower cost, the manufacturer’s copay assistance program if you have commercial insurance, independent foundations such as the Crohn’s & Colitis Foundation, Arthritis Foundation, PAN Foundation, or HealthWell Foundation, or asking your prescriber whether a different biologic would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Remicade, our team may be able to help you access assistance programs — or guide you to the much cheaper biosimilar path if it is the better fit. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.